Table 3 Clinical response evaluation during six-month treatment period and follow-up endpoint in CTX and CYA group patients
Characteristics | CTX group (n = 23) | CYA group (n = 24) | P value |
|---|---|---|---|
24hUP(g/d), M (P25, P75) | |||
One month | 3.37 (2.15, 6.21) | 5.22 (3.08, 10.43) | 0.18 |
Three months | 2.51 (1.28, 4.76) | 4.79 (2.80, 7.22) | 0.03 |
Six months | 1.37 (0.28, 2.41) | 2.26 (1.18, 4.79) | 0.05 |
Endpoint | 0.31 (0.12, 3.48) | 0.38 (0.22, 1.82) | 0.70 |
Scr (μmol/L), M(P25, P75) | |||
Six months | 69 (62, 86) | 77 (59, 85) | 0.48 |
Endpoint | 75 (62, 90) | 72 (58, 79) | 0.38 |
eGFR (ml/min per 1.73m2), mean ± SD | |||
Six months | 97.6 ± 26.5 | 98.4 ± 28.6 | 0.93 |
Endpoint | 97.1 ± 19.6 | 102.9 ± 30.7 | 0.44 |
Lymphocyte counts (×109/L) | |||
One month | 2.73 ± 1.40 | 3.18 ± 1.32 | 0.45 |
Three months | 2.44 ± 1.11 | 3.51 ± 1.57 | 0.01 |
Six months | 2.38 ± 1.29 | 3.37 ± 1.52 | 0.02 |
Endpoint | 2.22 ± 1.07 | 2.49 ± 1.03 | 0.39 |
Response at six-month’s follow -up [n (%)] | |||
Complete remission (CR) | 10 (43.5) | 5 (20.8) | 0.24 |
Partial remission (PR) | 9 (39.1) | 12 (50.0) | 0.24 |
Composite remission (CR + PR) | 19 (82.6) | 17 (70.8) | 0.34 |
No remission (NR) | 4 (17.4) | 7 (29.2) | 0.34 |
Median follow-up time (months), M (P25, P75) | 29 (23, 32) | 29 (15, 34) | 0.92 |
Response at follow-up endpoint, n (%) | |||
Complete remission (CR) | 13 (56.5) | 12 (50.0) | 0.10 |
Partial remission (PR) | 4 (17.4) | 9 (37.5) | 0.10 |
Composite remission (CR + PR) | 17 (73.9) | 21 (87.5) | 0.29 |
No remission (NR) | 3 (13.0) | 1 (4.2) | 0.29 |
Relapse | 3 (13.0) | 2 (8.3) | 0.67 |